ESCRS 2023: New artificial intelligence integrations are ahead for iCare

News
Video

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

Artificial intelligence (AI) was a popular topic at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) meeting. At the meeting, our team stopped by the iCare booth to see how AI is improving diagnostic speed and accuracy, for patients of all ages.


Editor's note: The below transcript has been lightly edited for clarity.

Kasperi Kankare: I'm Kasperi Kankare. I'm a key account manager at iCare Finland.

iCare has brought to the ESCRS this year 3 fantastic and unique solutions. We brought something new to glaucoma, we have brought the new iCare IC200, which is faster than ever and with its new quick measurement mode, it also enables measuring paediatric patients, from infants to the grownups, in a 200-degree angle, a complete freedom. Also we have iCare home, which enables the patient to do a home tonometry, which then can deliver the true intraocular pressure value to ophthalmologists and caregivers. And most importantly for glaucoma, we have now brought the new COMPASS. It delivers [an] absolutely fantastic visual field examination within just 4 minutes without [a] trial lens. I would enable the combined COMPASS with the iCare home. Because how you can treat glaucoma without knowing the true intraocular pressure of the patient?

On retina, iCare has always been leading a retina camera manufacturer. Our proprietary true color technology delivers a clear, high contrast image. The iCare ILLUME is the perfect marriage of our DRSplus fully-automatic retinal imaging solution, combined with a cloud service and artificial intelligence, which enables a caregiver to do a patient screening for 3 pathologies: diabetic retinopathy, AMD and glaucoma. Within a time period of 3 minutes from the imaging to the AI report. We have a lot of new interesting things upcoming. What I personally am awaiting most is to work with the artificial intelligence in ILLUME, because that is truly game-changing in our field.


Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.